Takeda faces ‘pay-for-delay’ class-action suit over anti-constipation drug
05-08-2021
Bogdanhoda / iStockphoto.com
Takeda has entered into an exclusive licensing agreement with biopharmaceutical company Tesaro to develop a novel cancer therapy in Japan.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Takeda, licensing agreement, patent, Tesaro, cancer therapy, biopharmaceutical
